Alaska Mental Health Board Advisory Board on Alcoholism and Drug Abuse 431 N. Franklin St. Suite 200 Juneau, Alaska, 99801



January 25, 2017

Representative Charisse Millett Alaska State Capitol, Room 404 Juneau, Alaska 99801

BY HAND-DELIVERY

Re: Letter of Support for HB 24

Representative Millett,

The Advisory Board on Alcohol and Drug Abuse and the Alaska Mental Health Board support the addition of the synthetic opioid U-47700 to the controlled substances schedule IA.

Deaths due to synthetic opioids and designer drugs have grown since 2015. The U.S. Drug Enforcement Agency noted the increase in deaths due to illicitly manufactured fentanyl and synthetic opioids in 2015, and then acted to regulate U-47700 by adding it to the federal controlled substances schedule I in November, 2016.

Of the opioid-related overdose deaths in Alaska since January 1, 2014, 29% involved fentanyl or synthetic opioids. The Division of Public Health reports that three of this deaths involved U-47700. Designer drugs like U-47700, like other opioids, pose a significant threat to the public health and safety of Alaskans. Acting to regulate U-47700 now, before greater impact occurs, is wise policymaking. The Boards appreciate your leadership in sponsoring HB 24.

Sincerely.

J. Kate Burkhart

**Executive Director** 

cc: Philip Licht, Chairperson, ABADA

Charlene Tautfest, Chairperson, AMHB

Dr. Jay Butler, Chief Medical Office, DHSS